Lakefront Biotherapeutics (GLPGF) Income from Continuing Operations (2014 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Income from Continuing Operations for 13 consecutive years, with -$50.4 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Income from Continuing Operations fell 128.39% year-over-year to -$50.4 million in Q2 2026; TTM through Jun 2026 was $328.5 billion, a 9859.55% increase from a year earlier, with the FY2025 full-year figure at $318.9 billion, up 9644.82% from the prior year.
• Income from Continuing Operations was -$50.4 million for Q2 2026 at Lakefront Biotherapeutics, down from $16.4 million in the prior quarter.
• Over five years, Income from Continuing Operations peaked at $329.1 billion in Q4 2025 and troughed at -$71.7 billion in Q4 2022.
• A 5-year average of $14.4 billion and a median of -$14.2 million in 2023 frame the typical range for Income from Continuing Operations.
• Across the five-year window, Income from Continuing Operations plunged 1076761.95% in 2022 and soared 10156.45% in 2025, its largest moves.
• Over 5 years, Income from Continuing Operations stood at -$71.7 billion in 2022, then jumped by 108.37% to $6.0 billion in 2023, then sank by 154.53% to -$3.3 billion in 2024, then soared by 10156.45% to $329.1 billion in 2025, then slumped by 100.02% to -$50.4 million in 2026.
• The last three Income from Continuing Operations figures came in at -$50.4 million (Q2 2026), $16.4 million (Q1 2026), and $329.1 billion (Q4 2025), per Business Quant data.